Mixed results for Shire in late stage lifitegrast trial

Shire (SHPG +0.8%) is out with top-line results from OPUS-2 (that's lifitegrast in dry eye patients).

Although the ophthalmic solution met its eye dryness co-primary endpoint, it did not meet the reduced corneal staining endpoint.

"We will be examining the totality of the data for lifitegrast in OPUS-2, as well as OPUS-1 and across the entire clinical trial program," CEO Flemming Ornskov says. (PR)

SHPG acquired the drug in the SARcode deal.

"The SARcode buyout was one of [Ornskov's] initial forays into ophthalmology," Jon Carroll notes, adding that "the mixed results in Phase 3 [are drawing] frowns from some analysts."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs